3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
51
Urinary Bladder Neoplasms
15
Breast Neoplasms
10
Carcinoma, Renal Cell
8
Colorectal Neoplasms
7
Neoplasms
6
Lung Neoplasms
6
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Non-Small-Cell Lung
4
Motor Activity
3
Colonic Neoplasms
3
Urologic Neoplasms
2
Urologic Diseases
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Recurrence
2
Rectal Neoplasms
2
Prostate Cancer Metastatic
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Melanoma
2
Kidney Neoplasms
2
Kidney Failure, Chronic
2
Esophageal Neoplasms
2
COVID-19
2
Breast Neoplasms, Male
2
Interventions
pembrolizumab
7
padeliporfin
5
Nivolumab
4
Everolimus
4
Sunitinib
3
Sorafenib
3
Mitomycin
3
fludarabine
2
epothilone B
2
durvalumab
2
cabozantinib
2
Ipilimumab
2
Cyclophosphamide
2
Cisplatin
2
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
volociximab
1
vinflunine
1
sipuleucel-T
1
sargramostim
1
pemigatinib
1
palladium-bacteriopheophorbide
1
palbociclib
1
obinutuzumab
1
luprolide acetate gel depot
1
lenvatinib
1
ixabepilone
1
fludarabine phosphate
1
enzalutamide
1
belzutifan
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Standard of Care
×
Genitourinary
×
Clear all
NCT01529411
2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2
Completed
86 enrolled